CARI Health
San Diego, US · Founded 2021 · Delaware corporation · 1 known investors
CARI Health develops a clinical testing platform that delivers rapid methadone concentration and metabolic data to clinicians at the point of care, enabling personalized dosing for opioid use disorder treatment. The platform helps reduce under- and over-dosing risks by providing data on patient metabolizer status (slow vs. fast) to improve treatment outcomes.
Founders & leadership
PS
Patrik SchmidleExecutive Officer, Director
GM
Gioia MessingerDirector
CP
Charles PattonDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$100KraisedJul 2025 · 2 investors · BiotechnologyRule 506(b)
▶$100KraisedJul 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrik SchmidleExecutive Officer, Director
- Charles PattonDirector
- Gioia MessingerDirector
- Offering amount
- $1M
- Amount sold
- $100K
- Minimum investment
- $25K
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$150KraisedFeb 2024 · 2 investors · BiotechnologyRule 506(b)
▶$150KraisedFeb 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles PattonDirector
- Patrik SchmidleExecutive Officer, Director
- Gioia MessingerDirector
- Offering amount
- $3M
- Amount sold
- $150K
- Minimum investment
- $50K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$2.3MraisedFeb 2024 · 11 investors · BiotechnologyRule 506(b)
▶$2.3MraisedFeb 2024 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gioia MessingerDirector
- Patrik SchmidleExecutive Officer, Director
- Charles PattonDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- Minimum investment
- $50K
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$800KraisedMay 2022 · 4 investors · BiotechnologyRule 506(b)
▶$800KraisedMay 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrik SchmidleExecutive Officer, Director
- Gioia MessingerDirector
- Charles PattonDirector
- Offering amount
- $2.2M
- Amount sold
- $800K
- Minimum investment
- $100K
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.